Skip to main content
Veterinary Medicines

FATROXIMIN 7,5 mg/ g intrauterinná a intravaginálna pena

Authorised
  • Rifaximin

Product identification

Medicine name:
FATROXIMIN 7,5 mg/ g intrauterinná a intravaginálna pena
Active substance:
  • Rifaximin
Target species:
  • Cattle (cow)
  • Horse (mare)
Route of administration:
  • Intrauterine use
  • Vaginal use

Product details

Active substance and strength:
  • Rifaximin
    100.50
    milligram(s)
    /
    1.00
    Container
Pharmaceutical form:
  • Intrauterine foam
Withdrawal period by route of administration:
  • Intrauterine use
    • Cattle (cow)
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Horse (mare)
      • Meat and offal
        0
        day
      • Milk
        0
        day
  • Vaginal use
    • Cattle (cow)
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Horse (mare)
      • Meat and offal
        0
        day
      • Milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG51AA06
Authorisation status:
  • Valid
Authorised in:
  • Slovakia
Available in:
  • Slovakia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 96/0636/97-S
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Slovak (PDF)
Published on: 14/12/2021
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."